RAPT RAPT Therapeutics

RAPT Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

RAPT Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Jan. 09, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients with inflammatory and immunological diseases, today announced that Brian Wong, M.D., Ph.D., President and Chief Executive Officer, will present a company overview at the 43rd Annual J.P. Morgan Healthcare Conference on Thursday, January 16, 2025 at 9:00 a.m. Pacific Time.

To access the live webcast or subsequent archived recording of the company presentation, please visit the RAPT Therapeutics website at .

About RAPT Therapeutics, Inc.

RAPT Therapeutics is a clinical-stage, immunology-based therapeutics company focused on discovering, developing and commercializing therapies for patients with inflammatory and immunological diseases. The company leverages its proprietary discovery and development platform to advance both biologics and selective small molecules aimed at normalizing critical immune drivers underlying these conditions.

RAPT Investor Contact:

Sylvia Wheeler

RAPT Media Contact:

Aljanae Reynolds



EN
09/01/2025

Underlying

RAPTRAPT Therapeutics

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on RAPT Therapeutics

 PRESS RELEASE
Free
RAPT RAPT Therapeuti...

RAPT Therapeutics to Participate in Upcoming Investor Conferences

RAPT Therapeutics to Participate in Upcoming Investor Conferences SOUTH SAN FRANCISCO, Calif., March 07, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients living with inflammatory and immunological diseases, today announced that members of the RAPT management team will participate in the following investor conferences in March: Leerink Global Healthcare Conference – Fireside chat on Tuesday, March 11, 2025 at 3:40 p.m. ET Bar...

March 7, 2025 1 EN
 PRESS RELEASE
Free
RAPT RAPT Therapeuti...

RAPT Therapeutics Reports Fourth Quarter and Full Year 2024 Financial ...

RAPT Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results SOUTH SAN FRANCISCO, Calif., March 06, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT) (“RAPT” or the “Company”) is a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients living with inflammatory and immunological diseases, today reported financial results for the fourth quarter and year ended December 31, 2024. “Our focus for 2025 will be on advancing development of RPT904, a novel, potential best-in-class ...

March 6, 2025 1 EN
 PRESS RELEASE
Free
RAPT RAPT Therapeuti...

RAPT Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare...

RAPT Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference SOUTH SAN FRANCISCO, Calif., Jan. 09, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients with inflammatory and immunological diseases, today announced that Brian Wong, M.D., Ph.D., President and Chief Executive Officer, will present a company overview at the 43rd Annual J.P. Morgan Healthcare Conference on Thursday, January 16, 2025 at 9:00 a.m. Pacifi...

January 9, 2025 1 EN
 PRESS RELEASE
Free
RAPT RAPT Therapeuti...

RAPT Therapeutics Names Lori Lyons-Williams Chair of the Company’s Boa...

RAPT Therapeutics Names Lori Lyons-Williams Chair of the Company’s Board of Directors SOUTH SAN FRANCISCO, Calif., Jan. 06, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients with inflammatory and immunological diseases, today announced the appointment of Lori Lyons-Williams as chair of its board of directors, succeeding William Rieflin, who stepped down from the board effective January 3, 2025. Mr. Rieflin will remain as a consulta...

January 6, 2025 1 EN
 PRESS RELEASE
Free
RAPT RAPT Therapeuti...

RAPT Therapeutics Announces $150 Million Private Placement

RAPT Therapeutics Announces $150 Million Private Placement SOUTH SAN FRANCISCO, Calif., Dec. 23, 2024 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based therapeutics company focused on discovering, developing and commercializing novel therapies for patients with significant unmet needs in inflammatory diseases, today announced that it has entered into a securities purchase agreement with a group of accredited investors for the private placement of (i) 100,000,000 shares of common stock at a purchase price of $0.85 per share and (ii) to certain i...

December 23, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch